Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities

Diabetes & Metabolism
L Monnier, C Colette

Abstract

There are many reasons to believe that in the near future, the treatment of patients with Type 2 diabetes will be characterised by an increased use of insulin therapy. To ensure that insulin regimens are acceptable to patients, and implemented by physicians, they should be as simple and efficient as possible. Simplicity is synonymous with the regimen of once-daily basal insulin glargine given at any time of the day (at the same time each day). With such a strategy, the dose is adjusted by titrating to target fasting blood glucose values of 5.0 - 7.2 mmol/L (90 - 130 mg/dL). When these targets can no longer be achieved with reasonable doses of long-acting insulin, a rapid-acting insulin analogue should be added at meal times. A step-by-step strategy can be used; it is recommended that initially, a single daily prandial bolus of a rapid-acting insulin analogue is administered before the meal that leads to the highest post-meal blood glucose excursions. Further boluses can be added at other meal times as necessary, i.e, when post-meal blood glucose values remain above 10.0 mmol/L (180 mg/dL) and 7.8 mmol/L (140 mg/dL) at mid-morning and 2h-post-lunch or post-dinner times, respectively. This stepwise strategy may eventually lead to...Continue Reading

References

Mar 1, 1984·Diabetes Care·C BinderS Pramming
Jan 1, 1996·Stroke; a Journal of Cerebral Circulation·S LehtoM Laakso
May 6, 1999·Diabetic Medicine : a Journal of the British Diabetic Association·Y GroeneveldM P Springer
Apr 24, 2001·Diabetes Care·H Yki-Järvinen
Sep 12, 2001·Lancet·D R OwensG B Bolli
Oct 22, 2002·Nihon rinsho. Japanese journal of clinical medicine·Mitsuyoshi Namba
Dec 25, 2004·Diabetes Care·UNKNOWN American Diabetes Association
Jan 14, 2005·The New England Journal of Medicine·Irl B Hirsch
Jan 29, 2005·Diabetes Care·Philip RaskinUNKNOWN INITIATE Study Group
Aug 5, 2005·Diabetologia·L Monnier, C Colette

❮ Previous
Next ❯

Citations

Jun 28, 2011·Diabetes Technology & Therapeutics·F Javier Ampudia-BlascoJuan F Ascaso
Sep 16, 2009·International Journal of Clinical Practice. Supplement·A Pfützner, T Forst
Jan 26, 2008·Current Medical Research and Opinion·Leonard C GlassRichard M Bergenstal
Apr 17, 2008·Journal of Diabetes and Its Complications·Nicole YurginMaureen J Lage
Feb 27, 2007·Diabetes & Metabolism·L MonnierH Boniface
Mar 2, 2013·Diabetes, Obesity & Metabolism·A J Garber
Aug 13, 2014·Diabetic Medicine : a Journal of the British Diabetic Association·C S S Frandsen, S Madsbad
Oct 22, 2008·Expert Opinion on Pharmacotherapy·Louis Monnier, Claude Colette
Sep 13, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Aliasghar A KiadaliriKatarina Steen Carlsson
May 15, 2015·Journal of Diabetes Science and Technology·Allen B King
Dec 23, 2016·Current Medical Research and Opinion·William V TamborlaneMichelle Van Name
Apr 23, 2017·Diabetes, Obesity & Metabolism·David R OwensAnthony H Barnett
Nov 4, 2009·Journal of Diabetes Science and Technology·Louis MonnierDavid R Owens
Jun 3, 2017·Diabetic Medicine : a Journal of the British Diabetic Association·D RaccahH Schmitt
Feb 13, 2010·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Satish GargMartin Pfohl
Mar 30, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Yujing JinTiehong Zhu
Feb 23, 2007·Diabetes/metabolism Research and Reviews·Denis RaccahMatthew Riddle
Mar 12, 2021·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Allen B King
Oct 18, 2007·Current Opinion in Endocrinology, Diabetes, and Obesity

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.